A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate changes in vascular parameters and the prevalence of
side effects in subjects receiving 1 cc (200mg) every 2 weeks intramuscular (IM) of
Testosterone Cypionate versus subjects receiving 11mg three times daily (TID) Natesto to
participant with clinical hypogonadism.